✓ Bengaluru
✓ ZCCK Registered
✓ ZCCK Registered
Gallbladder cancer is curable when caught early — but most cases present late. India has one of the world's highest rates. Incidentally discovered cancers after routine cholecystectomy need specialist re-operation within weeks. Expert HPB oncosurgery at Dhaara Liver Clinic, Yelahanka.
Gallbladder carcinoma is an adenocarcinoma arising from the gallbladder mucosal lining. It is the most common biliary tract malignancy and the 5th most common gastrointestinal cancer in India. The Indo-Gangetic belt (North India, including parts of Karnataka) has particularly high incidence — possibly related to Salmonella typhi infection, gallstone chronicity, and water composition.
The disease is insidious — it grows within the gallbladder wall silently, often without symptoms until it invades adjacent structures (liver, bile duct, duodenum, colon). By the time jaundice or a palpable mass appears, many tumours are unresectable.
The most important fact: approximately 25–30% of gallbladder cancers are discovered incidentally — found in the cholecystectomy specimen after routine removal for "gallstones". The initial surgery and what follows next determines survival.
The T stage (depth of tumour invasion into the gallbladder wall) is the single most important determinant of both operability and survival.
Lamina propria only. Simple laparoscopic or open cholecystectomy is curative. 5-year survival 85–100%.
Re-operation recommended — radical cholecystectomy + regional nodes. 5-year survival 70–80%.
Standard radical resection: segments IVb+V liver resection, lymphadenectomy, port-site excision. 5-year survival 50–65%.
Extended resection or unresectable. Vascular reconstruction in select cases. Chemotherapy for unresectable. 5-year survival 10–40%.
For T1a tumours discovered incidentally: simple cholecystectomy (laparoscopic or open) achieves cure. No re-operation needed if: margin is clear, no muscle invasion, no cystic duct involvement. Survival equals that of non-cancer cholecystectomy.
Standard operation for T1b–T3 tumours: resection of gallbladder + 2 cm margin of liver segments IVb and V (the gallbladder bed) + regional lymphadenectomy (hepatoduodenal ligament nodes). This is the curative intent operation for resectable gallbladder cancer.
When gallbladder cancer is found after laparoscopic cholecystectomy (incidental cancer), the trocar insertion sites carry risk of tumour implantation. All port sites must be surgically excised at the time of re-operation — a critical step often missed at non-specialist centres.
For T3 tumours with liver involvement: extended right hepatectomy, bile duct resection + hepaticojejunostomy, or combined liver-pancreas resection. High technical complexity requiring HPB specialisation. Volume and experience determine outcomes.
For unresectable disease causing obstructive jaundice: ERCP with biliary stenting or percutaneous transhepatic biliary drainage (PTBD) relieves jaundice and improves quality of life while chemotherapy is considered.
Gemcitabine + Cisplatin is standard first-line for unresectable or metastatic gallbladder cancer. FGFR inhibitors and immunotherapy (pembrolizumab in MSI-H tumours) have emerging roles. Dr. Srinivas coordinates with medical oncologists for multimodal care.
The pathology T stage dictates next steps. Bring the biopsy block if possible for re-review by an HPB-experienced pathologist — T1a vs T1b distinction is critical and can be misclassified.
Triple-phase CT to identify residual disease in liver bed, lymph node involvement, and distant metastases (lung, peritoneum). MRI liver with diffusion may add detail on liver involvement.
For T1b and above: plan radical cholecystectomy + port-site excision within 4–6 weeks of diagnosis. Delay increases risk of peritoneal spread and lymph node metastasis. Do not wait for symptoms or a second scan.
All gallbladder cancer cases are reviewed in a multidisciplinary tumour board including HPB surgery, medical oncology, radiation oncology, and radiology to determine the optimal treatment sequence.
Gallbladder cancer surgery has one of the highest rates of "declared inoperable, later found resectable" scenarios in GI oncology. Reasons include:
If you or a family member has been told gallbladder cancer is inoperable or that re-operation is not needed, a second opinion from a dedicated HPB oncosurgeon is strongly recommended before accepting that conclusion.
Gallbladder polyps and wall thickening can be benign (cholesterol polyps, adenomyomatosis) or malignant. Features that raise concern for cancer: polyp larger than 10 mm, sessile polyp (no stalk, flat base), rapidly growing polyp on serial imaging, focal wall thickening above 4 mm especially without stones, and any polyp in a patient above 60. If any of these apply, cholecystectomy and specialist evaluation are needed. Small pedunculated polyps under 6 mm can often be monitored with 6-monthly ultrasound. Do not ignore these findings — early surgery is curative.
This is called incidentally discovered gallbladder cancer (IDGBC) — it occurs in 0.3–1.5% of all cholecystectomies. What happens next depends entirely on T stage. If T1a (cancer only in the mucosa): your simple cholecystectomy may already be curative — the surgeon will review margins and decide if anything further is needed. If T1b, T2, or T3: re-operation is required. This involves open radical cholecystectomy — resecting the gallbladder bed of the liver (segments IVb and V), removing regional lymph nodes, and excising all trocar port sites from the laparoscopic operation. This re-operation should happen within 4–6 weeks. Do not delay — time matters significantly for lymph node spread.
Yes, strongly recommended. Gallbladder cancer resectability is highly technique-dependent. Extended resections involving vascular reconstruction, liver resections above segment V/IVb, and bile duct resection are complex procedures that are considered inoperable at some centres but are routinely performed at HPB speciality centres. Before accepting an inoperable verdict, have your CT scan reviewed by a dedicated HPB oncosurgeon with experience in extended biliary and vascular surgery. Second opinions have changed the management plan in a significant proportion of cases that were initially declared unresectable.
Early gallbladder cancer is usually asymptomatic — this is why so many cases are found incidentally. When symptoms do appear: right upper abdominal pain (similar to gallstone pain but more persistent), jaundice (yellow skin and eyes — means bile duct is blocked), dark urine and pale stools (biliary obstruction), unexplained significant weight loss, loss of appetite, nausea, and a palpable mass under the right rib cage. Jaundice combined with a gallbladder mass is an urgent finding requiring same-week evaluation — do not wait for a routine appointment.
Yes — cholecystectomy removes the gallbladder and therefore eliminates all future cancer risk from that gallbladder. For patients with large stones (above 3 cm), chronic cholecystitis, polyps, or anomalous pancreaticobiliary junction, the cumulative cancer risk over years justifies cholecystectomy. The operation is low risk (laparoscopic, day surgery or one-night stay) compared to the risk of developing gallbladder cancer. If you have known gallstones and have been delaying surgery, speak to a surgeon about timing.
Survival is strongly stage-dependent. T1a: 5-year survival 85–100% with curative cholecystectomy. T1b: 70–80% with radical re-operation. T2: 50–65% with complete radical resection at a specialist centre. T3 (into liver/adjacent structures): 20–40% with extended resection. T4 and metastatic: below 10% at 5 years despite chemotherapy. These numbers reinforce the importance of two things: appropriate initial surgery at the time of cholecystectomy, and immediate re-operation for incidentally discovered cancers. Delay and under-treatment are the most common reasons for poor outcomes.